Regeneron Pharmaceuticals Inc to Provide Updates Across its Oncology Portfolio Call Transcript

Sep 12, 2022 / 12:00PM GMT
Operator

Good day, and thank you for standing by. Welcome to the Regeneron ESMO 2022 Investor Event. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Ryan Crowe, Head of Investor Relations. Please go ahead.

Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Catherine. Good morning, good afternoon and good evening to everyone listening around the globe. Welcome to our ESMO 2022 Investor Call.

I would like to remind you that remarks made on this call today include forward-looking statements about Regeneron's business and research development programs, anticipated milestones and regulatory matters. Each forward-looking statement is subject to risks and uncertainties that could cause the actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update publicly

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot